REG - ConvaTec Group PLC - Scrip Dividend - Total Issued Shares

ConvaTecAnnouncement

28/04/2020 14:20

RNS Number : 1962L
  
ConvaTec Group PLC
  
28 April 2020
  
 

ConvaTec Group Plc
 
Scrip Dividend - Calculation Price
 
 
Reading, United Kingdom (28 April 2020)
The Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend in respect of 2019 of 3.983 cents per share ("Final Dividend"), subject to shareholder approval at the Annual General Meeting on 7 May 2020 ("AGM"). The Final Dividend is to be paid on 14 May 2020 to shareholders on the share register as at 3 April 2020 ("Record Date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 28 February 2020, the Company announced that a scrip dividend would be made available for the Final Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend was announced on 9 April 2020.
Subject to the approval of the Final Dividend at the AGM, 16,991,621 ordinary shares of 10 pence each will be allotted and issued on 14 May 2020 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.
Following the issue of shares under the scrip dividend scheme in respect of the Final Dividend, the Company's issued share capital will be 2,000,505,472 ordinary shares of 10 pence each.
Dealings in the shares issued under the scrip dividend scheme is expected to commence on 14 May 2020.
 
Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the Final Dividend are:




Ex-dividend Date


   2 April 2020


 




Record Date


3 April 2020


 




Scrip calculation price determined


2-8 April 2020 (inclusive)         


 




Scrip calculation price available and announced


                  9 April 2020


 




Mandate delivery deadline for Shares held in uncertificated form 


3.00 p.m. on 21 April 2020 


 




Mandate delivery deadline for Shares held in certificated form


5.00 p.m. on 21 April 2020 


 




  Announcement of the total amount of new shares to be issued


                         28 April 2020


 




  Dividend payment date


                         14 May 2020


 




  Dispatch of statement in accordance with section 7 of Scheme


                         14 May 2020 


 




Rules and share certificates, CREST accounts credited/updated, 
and first day of dealings in New Shares
                                                                                                           
 
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec            +44 (0)7551 036 625
ir@convatec.com
 
Media
Buchanan: Charles Ryland / Chris Lane / Vicky Hayns             +44 (0)207 466 5000                                                                                                           
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
 
 
 
 
# # #
END
 
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DIVFLFIVSIITFII